Plain-English translation of NCT06566807 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for marginal zone lymphoma, a type of blood cancer. The study combines two medications—orelabrutinib and obinutuzumab—to see if they work well together to shrink tumors and help patients get better. This combination is being tested in patients who have never been treated for this lymphoma before.
Currently, doctors don't have a standard treatment plan for newly diagnosed marginal zone lymphoma, and many existing treatments are harsh and cause serious side effects. This trial is exploring whether this new medication combination can work effectively without requiring chemotherapy, offering patients a safer option.
You likely qualify if…
You likely don't qualify if…
You would receive the two-drug combination as your treatment for 6 cycles (each cycle typically lasts a few weeks). If your lymphoma improves, you would then receive the medication as a single agent for one year to help keep the cancer from coming back. Throughout the trial, you'll have regular blood tests, imaging scans, and clinic visits so doctors can monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Huai'an First People's Hospital
Enrollment target
~51 participants
Started
August 2024
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chunling Wang
Huai'an First People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.